Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHEAD 3-45 Study: Lecanemab in Preclinical Alzheimer's Disease
NCT04468659Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Dec 2028
- Countries
- 7
01
Overview
A Phase 3 trial of lecanemab in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Jul 2020; status: active, not recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04468659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468659.